Indeed, PD-L1 expression in the plasma of patients with several tumor types is correlated with a worse patient outcome and weaker immune responses (Chen et al., 2018; Theodoraki et al., 2018; Yang et al., 2018; Fan et al., 2019; Kim et al., 2019; Li C. et al., 2019; Xie et al., 2019). Here, CD274 is linked to neoplasm.